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in those under 16 years of age: Are
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INTRODUCTION
Children and young people need safe and
effective medicines that reﬂect their chan-
ging physiological emotional and psycho-
logical status. Ethical and legal tensions
arise in the testing of medicines, especially
those that are connected with sexual
health and sensitive questions of behav-
iour and lifestyle. Young people’s freedom
to explore their developing sexuality and
independence has to be set against the
need to protect them from abuse and
exploitation, and the associated risks of
pregnancy and sexually transmitted
diseases.
Safe and effective contraception for
young people under 16 years of age is
considered an important part of the
overall campaign to reduce teenage preg-
nancies. However, these agents are not
well tolerated in this age group, and there
has been limited research to address this.
Despite recent welcomed clinical trials of
investigational medicinal products
(CTIMP) applications to research ethics
committees (RECs) in the UK, concern
has been raised about the ethical and legal
situation surrounding the proposed inclu-
sion into such studies of those as young as
12 years of age.
Research protocols for CTIMPs must
conform to regulatory and legal frame-
works and be reviewed and approved by
RECs before proceeding.
12Little formal
guidance exists as to how RECs might
address proposals to conduct safety and
efﬁcacy trials of contraceptive agents in
young people under the age of 16.
The purpose of this paper is to consider
the ethical and legal issues posed by such
proposals and suggest how guidance
might be framed.
BACKGROUND
There are strong socio-biological and
demographic reasons to consider the
development of contraceptive agents for
children under the age of 16 years.
Despite a recent fall in conception rates in
13–15 year olds, the UK still has the second
highest teenage pregnancy rate in the devel-
oped world.
34Although 70%–75% of preg-
nancies in this age group occur in 15 year
olds, over 1000 pregnancies per annum
occur in younger individuals,
3 and preg-
n a n c yh a sb e e nr e p o r t e di n1 2y e a ro l d s .
5
Both the age of menarche (mean
12.7 years; range 7–17)
6 and that of ﬁrst
sexual experience (median 16 years)
7 have
fallen over time. In the last UK national
survey of sexual attitudes and lifestyle, up to
40% of 15 year olds had some form of
sexual experience
8 and one-in-ﬁve 13
year olds stated that they had taken part in
oral or penetrative sex. It is accepted that
younger individuals tend to use less effective
methods of contraception, for example,
condoms or methods that are reliable in
older women, less effectively—for example,
oral contraceptive agents.
4 Suggestions that
10%–15% of adolescents on hormonal
contraception still get pregnant are logical
corollaries of the high incidence of reported
side effects, especially breakthrough bleed-
ing, experienced in younger women, with
consequently high discontinuation rates in
the younger age groups.
9 There is less
experience with the use of potentially more
effective methods, for example, long-acting
reversible contraceptives (LARCs) and
perhaps concomitant reluctance to use them
in this age group.
10 11
Despite this, recent applications to
undertake CTIMPS of contraceptive
agents in UK children as young as
12 years of age have highlighted both the
ethical and the legal issues involved and
the practical implications for RECs,
researchers and the children and their
families themselves.
These concerns aside, health risks and
adverse socio-economic consequences
provide strong imperatives to reduce
teenage pregnancy rates. Educational
interventions
12 the growth of abstinence
programmes,
13 attitudinal shifts towards
continuing education and the perceived
stigmatisation of teenage parenthood may
have played a role in the reduction of
teenage pregnancy rates in the USA and
the UK.
14 Despite this, the need for safe,
effective contraceptive agents remains.
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Adults with capacity are free to make
their own choices about contraception.
The importance of this freedom has been
regarded as sufﬁcient to overcome moral
and religious objections to contraception.
Young people, who are perceived as
lacking capacity and being vulnerable to
coercive inﬂuences, may not be granted
this freedom. But if they can demonstrate
sufﬁcient capacity to make free choices
over sexual activity and relationships, and
do understand the implications for them-
selves and their families, denial of access
to contraception advice and treatment
seems manifestly unjust. Regardless of
capacity, young people should have access
to appropriate information, for example,
by education about relationships and
sexual health, which will enable them to
exercise future choice. It can be argued
that society should not intervene in
intensely personal choices made by those
with capacity, irrespective of age, unless it
is to prevent harm to others. But society
does restrict some choices by age, for
example, marriage, because of the serious-
ness of the decision or because it has legit-
imate interests in the outcome.
Even if there are concerns that young
people may be unable to exercise free
choices over conception, there is still an
obligation to protect young people against
the risk of pregnancy that contraception
may avert. Easy access to contraception
neither necessarily increases the risk of
sexual activity nor the harms associated
with it, for example, sexually transmitted
diseases.
15 Indeed, the provision of conﬁ-
dential contraceptive advice and treatment
provides an opportunity for education
and personal discussion of sexual health
matters that is consistent with profes-
sionals’ duty of care to their patients.
Overall, given the same objectives of
preventing unwanted pregnancy, the use
of contraceptive agents, especially those
that prevent ovulation, fertilisation or
implantation, appear to engender less sus-
tainable moral objections than those pro-
duced by termination. Contraception
produces less physical and psychosocial
harms than termination of pregnancy, an
important consideration given that
approximately 60% of pregnancies in chil-
dren under the age of 16 years are
terminated.
Legal considerations
In the UK, individuals under the age of
16 can receive contraceptive advice and
treatment without the knowledge or
consent of their parents, provided they
have the capacity to consent. In England
and Wales, this is deﬁned as the ability to
understand fully the nature and purpose
of what is proposed and its implications
for themselves and their family (Gillick
competence).
16 Professionals should
satisfy themselves that the young person
fulﬁls Fraser’s guidelines for provision of
contraception (box 1). In Scotland, a
young person’s capacity to consent to
medical treatment is determined by the
professional providing the treatment.
17
In both jurisdictions, young people are
owed the same duty of conﬁdentiality as
adults. Conﬁdentiality may only be brea-
ched when the health, safety and welfare
of the young person or others would be at
grave risk, for example, from abuse or
exploitation.
18
Most jurisdictions have legislation
intended to protect young people from
abuse and exploitation that may accom-
pany some forms of adolescent sexual
behaviours. In England and Wales, the age
of consent for sexual activity (of whatever
orientation) as speciﬁed in the Sexual
Offences Act (SOA) 2003 is 16 years.
19
While sexual activity below this age is
technically a criminal offence, the serious-
ness with which it is regarded depends on
the ages of those involved and whether
there is evidence of—or good reason to
suspect—abuse, exploitation or coercion.
Prosecution of young people of similar
age and understanding, and who engage
in mutually consensual sexual activity is
not usually regarded as being in the public
interest. However, children under the age
of 13 years of age are regarded as lacking
the capacity to give valid consent to
sexual activity and such activity is a
serious offence.
19
Although it is an offence under the
SOA to aid, abet, counsel or otherwise
facilitate sexual offences in children under
the age of 16 years, professionals are spe-
ciﬁcally permitted to give contraceptive
advice or treatment intended to prevent
pregnancy or promote the child’s physical
or emotional well-being, though a lower
age limit is not speciﬁed.
19 20
Under the Clinical Trial Regulations
2004, a minor, for CTIMP purposes, is
anyone under the age of 16 years.
21 The
preamble to the European Clinical Trials
Directive (EC2001/20),
22 which the
Clinical Trial Regulations transposed into
UK law, set out fundamental ethical prin-
ciples. It helpfully contrasted the usual
restrictive concept of only including chil-
dren in CTIMPs when there are grounds
to expect administration of the IMP to be
of direct beneﬁt to them, thereby out-
weighing risks, with the overwhelming
need for research in children per se.
Medicinal products likely to be of signiﬁ-
cant value for children and young people
must be fully studied. So, the case that
contraceptive investigational medicinal
products (IMPs) ought to be tested in
young people in whom they are likely to
be used, and helpful, for example, those
between 13 and 16 years of age, seems
likely to be lawful under the European
directive, but for younger age groups this
might well not be the case.
Practical implications
Existing guidance on the provision of
contraceptive services for young people
from menarche onwards have speciﬁed
that age alone should not limit contracep-
tive choices provided medical eligibility
criteria are met.
23 24 Most emphasise the
requirement to provide young people with
sufﬁcient information on contraceptive
methods to enable them to make choices
that suit their needs and preferences.
52 32 5
However, there are little trial data on
which to base speciﬁc recommendations
about safe and effective contraception for
young people in the UK. This is particu-
larly so with respect to LARCs,
20 26
although they as a class may have proper-
ties that make them more suitable for
young people than alternatives currently
used and are more frequently used in
Europe.
11
Contraceptive agents are prescribed, but
often without licence, in adolescents for a
wide range of non-contraceptive indica-
tions such as treatment of delayed puberty
Box 1 The ‘Fraser Guidelines’ state
that all the following requirements
should be fulﬁlled
▸ The young person will understand the
professional’s advice.
▸ The young person cannot be
persuaded to inform their parents.
▸ The young person is likely to begin,
or to continue having, sexual
intercourse with or without
contraceptive treatment.
▸ Unless the young person receives
contraceptive treatment, their
physical or mental health, or both,
are likely to suffer.
▸ The young person’s best interests
require them to receive contraceptive
advice or treatment with or without
parental consent.
Gillick v. West Norfolk and Wisbech Area
Health Authority (1985)
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periods, dysmenorrhoea).
27 Whatever
their application, safety and efﬁcacy
should be determined in appropriate clin-
ical trials in relevant age groups.
12This is
especially important in adolescence when
pharmacokinetics, therapeutic effects, side
effects and future impact of any complica-
tions of medications can rarely be accur-
ately obtained from studies in adults or in
different species.
Neither ethical nor legal considerations
provide valid reasons to exclude 13–15
year olds from trials of contraceptive
agents, subject to appropriate ethical
approval. Such approval can be granted if
there is a sound scientiﬁc basis, a deﬁned
clinical need and prospect of beneﬁt to the
individual or the class they represent, pro-
vided that there is minimal risk and
minimal burden.
1 Advances in understand-
ing of adolescent brain development have
provided greater insight into both adoles-
cent risk-taking behaviours and their cap-
acity to assimilate and process information
relating to research trials.
28 Moreover, the
capacity of 14 year olds to provide
informed consent for research or treat-
ment is indistinguishable from that of
adults.
29 30 But, in contrast to provision of
contraceptive advice or treatment (which
can occur without parental consent or
knowledge for those who are Gillick com-
petent
16), participation of under 16s in
CTIMPs requires consent of a legally
designated representative (usually a parent)
as well as the subject’s agreement,
2 even
though the latter’s refusal will be hon-
oured. This potential requirement for par-
ental consent poses practical difﬁculties for
the conduct of contraceptive trials in
under 16s since adolescents value strongly
the right to conﬁdentiality in sexual health
matters
31 and are owed the same duty of
conﬁdentiality as adults.
18
Trial designs will need to overcome this
potential problem as well as recognising the
possibility that 13-year old to 15-year-old
participants could be subject to abuse,
exploitation or coercion, from which they
need safeguarding. Though there is no
mandatory statutory requirement to report
sexual activity in this age group in the UK,
there is strong presumption that reasonable
suspicions of abuse or exploitation will be
discussed with designated or named child
safeguarding professionals and an appropri-
ate strategy agreed and documented.
32–34
Clinical trials units undertaking such
research must have protocols in place,
reviewed and accepted by local safeguard-
ing professionals, that deal with potential
disclosure of child sexual abuse, positive
pregnancy testing or other safeguarding
concern. They should be able to reassure
RECs that those who will be responsible for
recruiting young people to trials will have
appropriate training and competencies to
enable them to detect safeguarding con-
c e r n sa n dt oa c tu p o nt h e mi na c c o r d a n c e
with agreed protocols.
32
Trials that involve testing of contracep-
tive agents in children under the age of 13
years in the UK, perhaps with the intention
of licensing for wider global usage, are
more difﬁcult for RECs. Despite the pro-
tection to health professionals afforded by
the SOA, it remains problematic for UK
RECs to sanction trials of agents that
permit an activity to which the young
person cannot legally consent. Presumably,
RECs could sanction trials of agents that
had an acceptable primary therapeutic
purpose, for example, control of menstrual
conditions, even if there was a secondary
(unintended?) effect of contraception. We
would recommend that all such trials
should be discussed with the Health
Research Authority National Research
Advisors Panel before any favourable REC
decision enables the trial to proceed.
Those faced with granting ethical
approval of trials of contraception in chil-
dren <16 years of age need to be satisﬁed
that such trials are both scientiﬁcally justiﬁed
and lawful and that appropriate mechanisms
to respect conﬁdentiality and provide safe-
guards for participants are in place.
Based on our analysis, we suggest
simple guidance for those RECs tasked
with the review of contraceptive agent
investigative medical product studies in
children <16 years of age (box 2).
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